Genprex (GNPX) said Monday that it has completed the phase 1 dose escalation portion of a trial of Reqorsa gene therapy in combination with Tecentriq to treat extensive stage small cell lung cancer.
The company also said the Safety Review Committee has approved initiating the phase 2 expansion part of the trial.
Shares of Genprex were down 7% in recent trading.
Price: 1.10, Change: -0.07, Percent Change: -5.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。